Note that seniors are actually some of the biggest cohorts using the new GLP1 Receptor Agonists:

https://glp1.guide/content/senior-citizens-and-glp1-receptor...

Also as some other people have noted, those costs seem high now, but they're certain to go down over time (due to competition and other companies entering the market along with other countries), and almost certainly worth the cost -- type 2 diabetes can be very expensive, along with all the other effects from complications of obesity.

For example, Wegovy has actually been FDA approved for reducing heart disease risk:

https://glp1.guide/content/news-fda-approves-wegovy-for-redu...